Your browser is no longer supported. Please, upgrade your browser.
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own3.10% Shs Outstand107.31M Perf Week5.71%
Market Cap1.41B Forward P/E- EPS next Y-0.69 Insider Trans425.63% Shs Float47.02M Perf Month139.72%
Income-104.20M PEG- EPS next Q-0.29 Inst Own91.30% Short Float25.51% Perf Quarter512.23%
Sales32.50M P/S43.41 EPS this Y197.90% Inst Trans19.23% Short Ratio1.07 Perf Half Y367.58%
Book/sh0.82 P/B10.38 EPS next Y26.30% ROA-32.30% Target Price3.67 Perf Year147.02%
Cash/sh0.67 P/C12.65 EPS next 5Y- ROE-167.50% 52W Range1.03 - 9.40 Perf YTD148.83%
Dividend- P/FCF- EPS past 5Y23.30% ROI40.70% 52W High-9.47% Beta2.00
Dividend %- Quick Ratio1.50 Sales past 5Y69.70% Gross Margin91.70% 52W Low726.21% ATR0.81
Employees184 Current Ratio1.50 Sales Q/Q-97.80% Oper. Margin- RSI (14)78.63 Volatility13.40% 15.02%
OptionableYes Debt/Eq0.23 EPS Q/Q-63.70% Profit Margin- Rel Volume0.33 Prev Close8.48
ShortableNo LT Debt/Eq0.13 EarningsOct 29 BMO Payout- Avg Volume11.22M Price8.51
Recom2.30 SMA2083.06% SMA50175.33% SMA200304.49% Volume3,733,231 Change0.35%
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Jan-22-21 10:18AM  
Jan-20-21 12:13PM  
Jan-15-21 08:31AM  
Jan-14-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 09:40AM  
Dec-31-20 08:00AM  
Dec-16-20 04:05PM  
Dec-12-20 04:03PM  
Dec-11-20 06:04PM  
Dec-09-20 09:22AM  
Nov-16-20 10:02PM  
Nov-06-20 07:48AM  
Oct-29-20 10:05AM  
Oct-27-20 08:00AM  
Sep-23-20 06:43PM  
Sep-14-20 09:46AM  
Sep-08-20 04:05PM  
Sep-04-20 08:00AM  
Sep-03-20 06:00PM  
Aug-24-20 11:35AM  
Aug-10-20 11:52AM  
Aug-03-20 07:25AM  
Aug-02-20 09:54AM  
Jul-30-20 06:00PM  
Jul-23-20 07:00AM  
Jul-22-20 12:32PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-14-20 01:19PM  
Jul-04-20 02:02PM  
Jun-13-20 11:01AM  
Jun-11-20 05:22PM  
May-27-20 07:00AM  
May-13-20 05:30PM  
Apr-27-20 06:33PM  
Apr-22-20 05:41PM  
Apr-20-20 10:04AM  
Apr-07-20 07:00AM  
Mar-30-20 11:11AM  
Mar-20-20 07:44AM  
Mar-19-20 04:01PM  
Mar-13-20 08:05AM  
Mar-12-20 01:40PM  
Mar-05-20 07:00AM  
Mar-04-20 12:30PM  
Jan-24-20 03:00PM  
Jan-20-20 04:01PM  
Jan-09-20 02:50PM  
Jan-06-20 06:09PM  
Dec-20-19 08:31AM  
Dec-19-19 08:28PM  
Dec-13-19 08:52AM  
Dec-05-19 12:54PM  
Dec-03-19 07:00AM  
Dec-02-19 11:09AM  
Nov-26-19 04:01PM  
Nov-15-19 11:17PM  
Nov-14-19 08:09PM  
Nov-13-19 08:39AM  
Nov-07-19 11:15AM  
Oct-31-19 04:01PM  
Oct-30-19 10:34AM  
Oct-29-19 07:05AM  
Oct-15-19 11:29AM  
Oct-13-19 05:15PM  
Oct-02-19 04:01PM  
Sep-30-19 10:05AM  
Sep-23-19 08:54AM  
Sep-18-19 08:42AM  
Sep-15-19 11:18AM  
Sep-11-19 07:42PM  
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artal International S.C.A.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:43 PM
Invus Public Equities, L.P.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:39 PM
SOBECKI CHRISTOPHER JDirectorApr 26Option Exercise0.003,4660140,759Apr 27 04:48 PM
Swain Judith LDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:49 PM
Palantoni FrankDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:48 PM
NIES ALAN SDirectorApr 26Option Exercise0.003,466017,082Apr 27 04:47 PM
DEBBANE RAYMONDDirectorApr 26Option Exercise0.003,4660316,883Apr 27 04:45 PM
LEFKOWITZ ROBERT J MDDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:46 PM
BARKER SAM LDirectorApr 26Option Exercise0.003,466055,653Apr 27 04:44 PM
Amouyal PhilippeDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:43 PM